

# ArthroFLEX<sup>®</sup> SCR

The Gold Standard for Superior Capsular Reconstruction

## Superior Capsular Reconstruction (SCR)

*Reconstruction of the superior capsule using ArthroFlex to provide a supplemental covering to the glenohumeral joint which keeps the humeral head centered on the glenoid, thereby restoring normal joint biomechanics and stability.*

## Why perform SCR?

- Restores glenohumeral joint stability, allowing return of function and ROM<sup>1-4</sup>
- Reduces pain and improves patient-reported outcome scores<sup>1-4</sup>
- Increases acromiohumeral distance<sup>3</sup>
- Allograft tissue that has been shown to incorporate versus metal and plastic solutions<sup>5</sup>
- Minimally invasive – can be performed arthroscopically<sup>1-4</sup>
- Viable alternative to arthroplasty<sup>1,3,4</sup>

“Our data showed SCR with dermal allograft effectively restored the superior restraints in the glenohumeral joint and yielded outstanding clinical outcomes even after 2 years, making it an excellent viable alternative to RTSA.”<sup>3</sup>

*(Hirahara et al, 2017)*



# Not all ADMs are the same.

ArthroFlex is the only truly “**decellularized**” acellular dermal matrix (ADM) for use in Superior Capsular Reconstruction.

Although several dermal products claim to be “decellularized”, not all decellularization processes meet the definition developed by Crapo, Gilbert and Badylak.<sup>7</sup> After evaluating remodeling responses and adverse cell and host responses, the authors determined that an ADM needs to meet certain criteria to satisfy the intent of decellularization.

Inadequate decellularization leaves DNA and residual cellular material in allografts that can elicit adverse host reactions and negate constructive tissue remodeling.



## ArthroFlex has been shown to meet these decellularization criteria:

*Lack of visible nuclear material in tissue*

*<50 ng dsDNA per mg ECM dry weight*

**Histology demonstrates removal of DNA and potentially immunogenic components**

**ArthroFlex has been shown to contain less than 10 ng DNA/mg dry tissue**



# Decellularization and Preservation Technology Platforms Deliver Results while Preserving the Graft's Natural Ultrastructure.



Process	Chemicals	Mode of Action and Potential impact
<b>Matracell® Technology</b> (ArthroFlex)	<ul style="list-style-type: none"> <li>N-Lauroyl sarcosinate (NLS)</li> <li>Endonuclease</li> </ul>	<ul style="list-style-type: none"> <li>Non-denaturing detergent that effectively and efficiently solubilizes and removes cells and cellular remnants from the tissue while leaving the ECM biomechanically and physiologically intact.<sup>5</sup></li> <li>Effectively fragments DNA for removal.<sup>7</sup></li> </ul>
<b>Tutoplast®</b> (Matrix HD®)	<ul style="list-style-type: none"> <li>Acetone</li> <li>Sodium hydroxide</li> <li>Hydrogen peroxide</li> <li>Hydrogen peroxide</li> </ul>	<ul style="list-style-type: none"> <li>Removes lipids from tissue<sup>8</sup>, but crosslinks and precipitates proteins, including collagen.<sup>7</sup></li> <li>Reduces prion infectivity,<sup>8</sup> disrupts nucleic acids and may damage collagen, GAG, and growth factors.<sup>7</sup></li> <li>Oxidative treatment to remove soluble proteins and destroy viruses and bacterial spores.<sup>8</sup></li> <li>May damage collagen, GAG, and growth factors.<sup>7</sup></li> </ul>
<b>Other Known Processing Reagents</b> (GraftJacket® AlloPatch HD®)	<ul style="list-style-type: none"> <li>PolySorbate 20</li> <li>Peracetic Acid</li> <li>NaCl</li> <li>Triton</li> </ul>	<ul style="list-style-type: none"> <li>May disrupt and dissociate proteins in the ECM.<sup>7</sup></li> <li>Disinfection agent that can remove residual nucleic acid<sup>7</sup> but does not sufficiently remove cells.<sup>12</sup></li> <li>Lyses cells, but does not effectively remove cellular residues.<sup>7</sup></li> <li>May effectively remove cell from tissue, but disrupts ECM.<sup>7</sup></li> </ul>
<b>“Proprietary”</b> (AlloMend® Coll-e-Derm™)	<ul style="list-style-type: none"> <li>Unknown</li> </ul>	<ul style="list-style-type: none"> <li>Unknown impact on tissue</li> </ul>




- Creates an environment that prevents free-water mediated degradation of the ECM<sup>14</sup>
- Maintains handling & suturability
- Allows for long term ambient storage.<sup>13</sup>
- No impact to graft.<sup>13</sup> Growth factors are retained.<sup>13</sup>


Other preservation methods such as ethanol, sterile water, freeze-drying and solvent dehydration may be less expensive; but they can also damage the ECM and negatively impact its biomechanical and biochemical properties.<sup>7,9,10</sup>



# Biological Incorporation of ArthroFlex in Superior Capsular Reconstruction for Irreparable Rotator Cuff Repair.<sup>5</sup>



Cross-sectional view of quarter 1. Medial glenoid attachment is to the right, articular side is at the bottom of the image.



Identified fibrocartilage on explanted ArthroFlex.

## Case Study\*


### SCR with ArthroFlex SCR performed in 2015

- Sustained shoulder injury 10 weeks post-operative, and MRIs showed repair failure - suspected to be as a result of the fall.
- Graft explanted during a debridement surgery 13 months post-operative.


The graft was explanted during a debridement surgery 13 months post-op, sent to LifeNet Health courtesy of Dr. Lederman and prepared for histological analysis

## Histological Analysis


The explant sample was dissected to four quarters via the mid-line, formalin-fixed, paraffin-embedded, cross-sectioned, and stained with hematoxylin and eosin (H&E) for analysis. Histological analysis showed that ArthroFlex maintained the acellular dermal matrix structure. Infiltrated fibroblast-like cells and neovascularization were present. The center of the ArthroFlex tissue remained acellular and avascular, while no signs of necrosis or calcification were observed. Tendon-like tissue structure was found near the glenoid attachment point.



Abundant blood vessel formation on explanted ArthroFlex.



Recellularization observed on explanted ArthroFlex.



Tendon-like structures noted on explanted ArthroFlex.

\* Results from case studies are not predictive of results in other cases. Results in other cases may vary.

## Why Use ArthroFlex SCR?

- ▶ **ArthroFlex is the only truly decellularized ADM with published clinical results for SCR**
- ▶ **ArthroFlex SCR has been shown to be clinically effective<sup>1-4,6</sup>**
- ▶ **Shown to restore anatomy and biomechanical properties<sup>1-4,6</sup>**
- ▶ **Shown to revascularize, remodel and incorporate<sup>5,13</sup>**
- ▶ **Excellent ultimate load and suture retention strength<sup>5,13</sup>**
- ▶ **Ready to use and excellent handling**

**To order: Contact your local LifeNet Health Representative  
or Arthrex Technical Consultant.**

Order Code	Size
AFLEX301	4 x 7 cm, 2.5 - 3.5 mm thickness
AFLEX300	4 x 5 cm, 2.5 - 3.5 mm thickness

### References

1. Adams, CR, Denard PJ, Brady PC, Hartzler RU & Burkhart SS. The Arthroscopic Superior Capsular Reconstruction. *AJO*. 2016 Jul/August; 45(5):320-4.
2. Tokish JT & Beicker C. Superior Capsule Reconstruction Technique Using an Acellular Dermal Allograft. *Arthroscopy Techniques*. 2015 Dec 4(6):e833-9.
3. Hirahara AM, Anderson WJ & Panero AJ. Superior Capsular Reconstruction: Clinical Outcomes After Minimum 2-Year Follow-Up. *AJO*. 2017 Nov/Dec; 46(6):266-272,278.
4. Denard PJ, Brady PC, Adams CR, Tokish JM, & Burkhart SS. Preliminary Results of Arthroscopic Superior Capsule Reconstruction with Dermal Allograft. *Arthroscopy*. 2018 Jan;34(1):93-99.
5. Date on file at LifeNet Health: 68-20-168, 65-0272.
6. Pennington WT, Bartz BA, Pauli JM, Walker CE, Schmidt W. Arthroscopic Superior Capsular Reconstruction with Acellular Dermal Allograft for the Treatment of Massive Irreparable Rotator Cuff Tears: Short-Term Clinical Outcomes and the Radiographic Parameter of Superior Capsular Distance. *Arthroscopy* 2018. Feb 15
7. Crapo PM, Gilbert TW & Badylak SF. An overview of tissue and whole organ decellularization processes. *Biomaterials*. 2011. April;32(12):3233-3243.
8. Schoepg, C. The Tutoplast® Process: A Review of Efficacy. 4627 R0 02-28-08
9. Ross A & Kearney JN. The measurement of water activity in allogeneic skin grafts preserved using high concentration glycerol or propylene glycol. *Cell and Tissue Banking*. 2004. Jan; 5:37-44.
10. Badylak SF, Freytes DO & Gilbert TW. Extracellular matrix as a biological scaffold material: Structure and function. *Acta Biomaterialia*. 2009. Jan; 5(1):1-13.
11. Ketchedjian A, Jones AL, Krueger P, Robinson E, Crouch K, Wolfenbarger Jr L, Hopkins R. Recellularization of Decellularized Allograft Scaffolds in Ovine Great Vessel Reconstructions. *Ann Thorac Surg*. 2005;79:888-96.
12. Gilpin A and Yang Y. Decellularization Strategies for Regenerative Medicine: From Processing Techniques to Applications. *Biomed Res Int*. 2017: PMC5429943.
13. Moore MA, Samsell B, Wallis G, Triplett, S, Chen S, Linthorst Jones A, Quiz X. "Decellularization of Human Dermis Using Non-Denaturing Anionic Detergent and Endonuclease: A Review." *Journal of Cell and Tissue Banking*.
14. Choe JM, Bell T (2001) Genetic material is present in cadaveric dermis and cadaveric fascia lata. *J Urol* 166:122-124
15. Derwin KA, Baker AR, Spragg RK, Leigh DR, Ianotti JP. Biomechanical, Biochemical, and Cellular Properties Commercial Extracellular Matrix Scaffolds for Rotator Cuff Tendon Repair. *J Bone Joint Surg Am*. 2006;88:2665-2672.


ArthroFlex, Matrancell, Preservon and the LifeNet Health logo are registered trademarks of LifeNet Health. Tutoplast and Matrix HD are registered trademarks of RTI Biologics. Graftjacket is a registered trademark of Wright Medical. AlloPatch HD is a registered trademark of MTF Biologics. AlloMend is a registered trademark of AlloSource. Coll-e-Derm is a trademark of Parametrics Medical. © 2019 LifeNet Health. All rights reserved.



[LifeNetHealth.org](http://LifeNetHealth.org)

# ArthroFLEX<sup>®</sup> SCR

The Gold Standard for Superior Capsular Reconstruction



## TECHNICAL OVERVIEW

The proven acellular dermal matrix (ADM) fueled by innovation and backed by clinical outcomes.

